Influence of multidrug resistance and appropriate empirical therapy on the 30-day mortality rate of Pseudomonas aeruginosa bacteremia.
about
Surveillance and correlation of antimicrobial usage and resistance of Pseudomonas aeruginosa: a hospital population-based studyThe Use of Bloodstream Infection Mortality to Measure the Impact of Antimicrobial Stewardship Interventions: Assessing the EvidenceBloodstream infections and sepsis in Greece: over-time change of epidemiology and impact of de-escalation on final outcomePseudomonas aeruginosa urinary tract infections in hospitalized patients: Mortality and prognostic factors.Carbapenem-resistant Pseudomonas aeruginosa: association with virulence genes and biofilm formationClinical and economic consequences of hospital-acquired resistant and multidrug-resistant Pseudomonas aeruginosa infections: a systematic review and meta-analysis.A propensity score analysis shows that empirical treatment with linezolid does not increase the thirty-day mortality rate in patients with Gram-negative bacteremia.Frequency of occurrence and antimicrobial susceptibility of Gram-negative bacteremia isolates in patients with urinary tract infection: results from United States and European hospitals (2009-2011).Effect of metallo-β-lactamase production and multidrug resistance on clinical outcomes in patients with Pseudomonas aeruginosa bloodstream infection: a retrospective cohort study.Risk factors for mortality in patients with Pseudomonas aeruginosa bacteremia; retrospective study of impact of combination antimicrobial therapy.Management of Adults With Hospital-acquired and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society.Stenotrophomonas maltophilia Infections in Adults: Primary Bacteremia and Pneumonia.Outcomes in Documented Pseudomonas aeruginosa Bacteremia Treated with Intermittent IV Infusion of Ceftazidime, Meropenem, or Piperacillin-Tazobactam: A Retrospective Study.Outcomes of appropriate empiric combination versus monotherapy for Pseudomonas aeruginosa bacteremia.Successful Treatment of Multi-Drug Resistant Pseudomonas aeruginosa Bacteremia with the Recommended Renally Adjusted Ceftolozane/Tazobactam Regimen.Antimicrobial stewardship programs: mandatory for all ICUs.A cohort study of bacteremic pneumonia: The importance of antibiotic resistance and appropriate initial therapy?Stress responses as determinants of antimicrobial resistance in Pseudomonas aeruginosa: multidrug efflux and more.Management of multidrug-resistant Pseudomonas aeruginosa in the intensive care unit: state of the art.Ceftolozane/tazobactam for febrile UTI due to multidrug-resistant Pseudomonas aeruginosa in a patient with neurogenic bladder.Ceftolozane-Tazobactam Activity against Pseudomonas aeruginosa Clinical Isolates from U.S. Hospitals: Report from the PACTS Antimicrobial Surveillance Program, 2012 to 2015.Patient specific risk stratification for antimicrobial resistance and possible treatment strategies in gram-negative bacterial infections.Population Pharmacokinetics and Pharmacodynamics Modeling To Optimize Dosage Regimens of Sulbactam in Critically Ill Patients with Severe Sepsis Caused by Acinetobacter baumannii.Risk factors associated with unfavorable short-term treatment outcome in patients with documented Pseudomonas aeruginosa infection.A New Take on an Old Remedy: Generating Antibodies against Multidrug-Resistant Gram-Negative Bacteria in a Postantibiotic World.Successful treatment of three severe MDR or XDR Pseudomonas aeruginosa infections with ceftolozane/tazobactam.Activity of Ceftolozane-Tazobactam against Carbapenem-Resistant, Non-Carbapenemase-Producing Pseudomonas aeruginosa and Associated Resistance Mechanisms.Risk Factors and Outcomes for Ineffective Empiric Treatment of Sepsis Caused by Gram-Negative Pathogens: Stratification by Onset of Infection.Predicting Resistance to Piperacillin-Tazobactam, Cefepime and Meropenem in Septic Patients With Bloodstream Infection Due to Gram-Negative Bacteria.Therapies for multidrug resistant and extensively drug-resistant non-fermenting gram-negative bacteria causing nosocomial infections: a perilous journey toward 'molecularly targeted' therapy.Pseudomonas aeruginosa resistance patterns and clinical outcomes in hospitalized exacerbations of COPD.Comparison of mono- and combination antibiotic therapy for the treatment of Pseudomonas aeruginosa bacteraemia: A cumulative meta-analysis of cohort studies.The 22/11 risk prediction model: a validated model for predicting 30-day mortality in patients with cirrhosis and spontaneous bacterial peritonitis.Risk factors for mortality in patients with acute leukemia and bloodstream infections in the era of multiresistance.Lower neutrophil-to-lymphocyte ratio predicts high risk of multidrug-resistant infection in patients with hospital-acquired pneumonia
P2860
Q28535024-8F8D5EFA-C084-4ED1-BE28-9096BE9FF8C8Q33564316-F5C37A35-4A7C-443C-944C-25E8154AFA7FQ33673654-58C951A0-6402-40CF-9E86-160353DEBF4EQ33732032-86BC10AB-1B3B-421B-AFDF-1F710F4F34E1Q33796573-A603F85C-4023-465D-99A4-4CEC2B046551Q34446914-A2FDB3F2-D0A5-446D-9F62-85525A6225E3Q34597369-14B82555-50BA-414B-BD0D-C1E38024E0BCQ35007499-E93BE9AC-521E-41D0-B2D3-AD3D68B860B4Q35029541-6460C32A-0754-4B2F-B9D8-77913EE642B0Q35127299-9A11FCA6-F75F-42E8-BD4F-22F4550D6283Q36078359-60CCCF47-4D43-4EC3-9D78-CF961856E5D3Q36147564-435F5FE5-8080-41DC-8730-28CB9D66B993Q36161206-C465E931-B24B-4DC6-A073-78D04852C3E0Q36667202-F2F7ADA8-527B-4584-A2F2-952BB6DFE85EQ36740013-6E2AE294-3B4B-44EF-90FD-5BC30FE258CBQ36902730-B36FBF8F-9DF4-490F-98A5-348E67C4FD3BQ37226357-D98C2AF2-8541-44C5-AB17-BBF935827FBAQ38267242-746E1B8C-7320-455C-B934-7505DF7299F5Q40095692-3073C6B1-6681-4B25-A106-A88ABAF2C719Q40213320-99790EDD-DA5F-4321-BDC4-6D44F5AF897EQ40220974-24A274E5-8129-44B6-A57E-083477390F1CQ40494723-6693FD21-448E-4518-BDFA-0C2255FB6E02Q40526821-22F02684-1707-4591-A6B3-78E20B70DF6EQ41512238-979E0F37-906C-4E41-82AB-FAD6606E1506Q41989828-DD9E7F80-391E-4BAB-A751-51E8663173CEQ41990882-C8985AAB-EB2B-4888-8AEF-DC6E9BCA0D2FQ47218700-72375813-14D0-4A32-9A66-1063299E5A78Q47647007-2E263877-28A0-4D25-8457-D5BDCCDCC533Q47654446-78FBA3B9-979C-427E-B354-FE398D4604CFQ47661746-D8C6604E-9BE4-4507-AAA4-5052EF5282F9Q48051439-F234C346-A3D1-45DE-8AAF-8FCE7476F2B6Q49884441-1091BA22-0C58-4835-8BE9-DABD24733E12Q53097446-6F8FDE8C-55DC-4DDC-844F-B55560587E38Q55496879-AA557D8F-03FF-476A-9015-C8C8CB4E572DQ57485307-ACA4153F-5E4A-4D38-8A6B-39F49B4159EC
P2860
Influence of multidrug resistance and appropriate empirical therapy on the 30-day mortality rate of Pseudomonas aeruginosa bacteremia.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Influence of multidrug resista ...... domonas aeruginosa bacteremia.
@ast
Influence of multidrug resista ...... domonas aeruginosa bacteremia.
@en
type
label
Influence of multidrug resista ...... domonas aeruginosa bacteremia.
@ast
Influence of multidrug resista ...... domonas aeruginosa bacteremia.
@en
prefLabel
Influence of multidrug resista ...... domonas aeruginosa bacteremia.
@ast
Influence of multidrug resista ...... domonas aeruginosa bacteremia.
@en
P2093
P2860
P356
P1476
Influence of multidrug resista ...... udomonas aeruginosa bacteremia
@en
P2093
Cristina Hernández
Holguer Sterzik
José A Martínez
José Mensa
Laura Morata
Manel Almela
Nazaret Cobos-Trigueros
Raquel Núñez
P2860
P304
P356
10.1128/AAC.00750-12
P407
P577
2012-07-02T00:00:00Z